Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for steroid-refractory acute graft-versus-host disease in pediatric HSCT recipients
2008-006726-34Phase 2Active
- Sponsor
- Istituto Giannina Gaslini
- Start
- Mar 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Istituto Giannina Gaslini. Primary endpoints: Short-term safety and toxicity of etanercept, Long-term safety and toxicity of etanercept and 2 more. Started Mar 2009; status: active.
02
Drugs
etanercept
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2008-006726-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006726-34.